Patents
Literature
50 results about "PDE1" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
PDE1 (phosphodiesterase type 1) is a phosphodiesterase enzyme also known as calcium- and calmodulin-dependent phosphodiesterase. It is one of the 11 families of phosphodiesterase (PDE1-PDE11). PDE1 has three subtypes, PDE1A, PDE1B and PDE1C which divide further into various isoforms. The various isoforms exhibit different affinities for cAMP and cGMP.
Organic compounds
ActiveUS20120053190A1Useful in treatmentInhibitory activityBiocideOrganic active ingredientsPhosphodiesteraseBipolar mood disorder
The present invention relates to a new use of phosphodiesterase 1 (PDE1) inhibitors for the treatment of psychosis, schizophrenia, schizoaffective disorder, schizophreniform disorder, psychotic disorder, delusional disorder, mania, or bipolar disorder.
Owner:INTRA CELLULAR THERAPIES INC
Organic compounds
The present invention relates to a new use of phosphodiesterase 1 (PDE1) inhibitors for the treatment and / or prophylaxis of narcolepsy.
Owner:INTRA CELLULAR THERAPIES INC
Pde1 inhibitors for ophthalmic disorders
ActiveUS20110312978A1Reduce dosageEliminate side effectsBiocideOrganic active ingredientsDiseaseWhole body
Compounds that inhibit phosphodiesterase 1 (PDE1) are useful to treat glaucoma or elevated intraocular pressure. The PDE1 inhibitors may be administered as monotherapy or in combination with additional intraocular-pressure lowering agents. In addition, the invention provides ophthalmic compositions comprising PDE 1 inhibitors and optionally one or more additional intraocular pressure-lowering agents. Topical and systemic therapy may be used.
Owner:INTRA CELLULAR THERAPIES INC
Novel uses
InactiveUS20100323997A1Enhancement of signaling pathwayAmeliorate any conditionOrganic active ingredientsBiocideSexual functioningContragestazol
The present invention relates to a new use for compounds that inhibit phosphodiesterase 1 (PDE1), e.g., that inhibit PDE1-mediated suppression of the dopamine D1 receptor and / or progesterone signaling pathways, including, e.g., methods of treatment or prophylaxis for conditions which may be ameliorated by enhancing the progesterone signaling response, particularly female sexual dysfunction.
Owner:INTRA CELLULAR THERAPIES INC
Tricyclic guanidine derivative
InactiveUS20160083400A1Effective inhibitorBiocideOrganic chemistryGuanidine derivativesPhosphodiesterase
Disclosed are compounds useful as inhibitors of Phosphodiesterase 1 (PDE1), compositions thereof, and methods of using the same.
Owner:SUNOVION PHARMA INC +1
Tricyclic piperazine derivative
Disclosed are compounds useful as inhibitors of Phosphodiesterase 1 (PDE1), compositions thereof, and methods of using the same.
Owner:SUNOVION PHARMA INC +1
Method of treating female sexual dysfunction with a PDE1 inhibitor
The present invention relates to a new use for compounds that inhibit phosphodiesterase 1 (PDE1), e.g., that inhibit PDE1-mediated suppression of the dopamine D1 receptor and / or progesterone signaling pathways, including, e.g., methods of treatment or prophylaxis for conditions which may be ameliorated by enhancing the progesterone signaling response, particularly female sexual dysfunction.
Owner:INTRA CELLULAR THERAPIES INC
Phosphodiesterase 1-targeting tracers and methods
ActiveUS8858911B2High activityHigh purityOrganic active ingredientsBiocidePhosphodiesterasePositron emitters
Tracers targeting phosphodiesterase 1 for use in gamma radiation detection-based diagnostic techniques, particularly gamma-emitter labeled tracers for SPECT and positron emitter-labeled compositions for PET are disclosed. Radio-labeled multiple novel scaffolds as PDE1 inhibitors such as substituted pyrazolo-pyrimidin-4-one derivatives, biomarkers for phosphodiesterase 1 [PDE1) in vivo, methods for developing novel therapies for PDE1-implicated conditions such as pulmonary arterial hypertension (PAH), Central Nervous System (CNS) and Cardiovascular (CV) disorders, and methods of detection and treatment are also disclosed.
Owner:INTRA CELLULAR THERAPIES INC
Methods and compositions for the treatment or prevention of pathological cardiac remodeling and heart failure
The invention relates to methods of treating or preventing pathological cardiac remodeling and / or preventing heart failure. These methods include the administration of a PDE1 inhibitor to a patient under conditions effective to treat or prevent pathological cardiac remodeling, and therefore heart failure that occurs as a result of such remodeling. Pharmaceutical compositions and delivery vehicles that can be used in the methods of the present invention are also disclosed herein.
Owner:UNIVERSITY OF ROCHESTER
Organic compounds
The present invention relates to a new use of phosphodiesterase 1 (PDE1) inhibitors for the treatment of psychosis, schizophrenia, schizoaffective disorder, schizophreniform disorder, psychotic disorder, delusional disorder, mania, or bipolar disorder.
Owner:INTRA CELLULAR THERAPIES INC
Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as PDE1 inhibitors
ActiveUS10351561B2Avoid unnecessary influenceOrganic active ingredientsNervous disorderDiseaseMedicine
The present invention provides compounds of formula (I) that are PDE1 enzyme inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating disorders using the compounds of the invention.
![Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as PDE1 inhibitors](https://images-eureka.patsnap.com/patent_img/645005e9-7481-4f8c-b542-a0a96f750fd9/US10351561-C00001.png "Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as PDE1 inhibitors")
![Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as PDE1 inhibitors](https://images-eureka.patsnap.com/patent_img/645005e9-7481-4f8c-b542-a0a96f750fd9/US10351561-C00002.png "Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as PDE1 inhibitors")
![Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as PDE1 inhibitors](https://images-eureka.patsnap.com/patent_img/645005e9-7481-4f8c-b542-a0a96f750fd9/US10351561-C00003.png "Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as PDE1 inhibitors")
Owner:H LUNDBECK AS
1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
![1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors](https://images-eureka.patsnap.com/patent_img/640319c4-d2d1-4450-9cf6-b6e5705aa729/US20190194189A1-C00001.png "1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors")
![1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors](https://images-eureka.patsnap.com/patent_img/640319c4-d2d1-4450-9cf6-b6e5705aa729/US20190194189A1-C00002.png "1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors")
![1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors](https://images-eureka.patsnap.com/patent_img/640319c4-d2d1-4450-9cf6-b6e5705aa729/US20190194189A1-C00003.png "1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors")
Owner:H LUNDBECK AS
Novel combination
ActiveUS20160038494A1Promotes maladaptive hypertrophic gene expressionNegatively regulate cardiac hypertrophyOrganic active ingredientsBiocidePhosphodiesteraseEnkephalinase inhibitor
The invention relates to the combination of inhibitors of phosphodiesterase 1 (PDE1) and inhibitors of Neprilysin (NEP) useful for the treatment of certain cardiovascular diseases or related disorders, e.g., hypertension, congestive heart disease, and post-myocardial infarction. In another embodiment, the invention relates to the combination of inhibitors of PDE1 and inhibitors of NEP for the treatment of diseases or disorders characterized by disruption of or damage to various cGMP / PKG mediated pathways in the cardiovascular system (e.g., in cardiac tissue or in arterial smooth muscle).
Owner:INTRA CELLULAR THERAPIES INC
Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases
ActiveUS9801882B2Significant modulatory activityEnhancement of cGMPOrganic active ingredientsAntipyreticPhosphodiesteraseVascular disease
The invention relates to the administration of inhibitors of phosphodiesterase 1 (PDE1) for the treatment of diseases or disorders characterized by disruption of or damage to various cGMP / PKG mediated pathways. In one embodiment the invention relates to inhibitors of phosphodiesterase 1 (PDE1) for treatment of cardiovascular disease and related disorders, e.g., congestive heart disease, atherosclerosis, myocardial infarction, and stroke.
Owner:INTRA CELLULAR THERAPIES INC
Organic compounds
ActiveUS9546175B2Promote maladaptive hypertrophic gene expressionRegulating cGMP/PKGOrganic active ingredientsOrganic chemistryPhosphodiesteraseSimple Organic Compounds
The invention relates to novel inhibitors of phosphodiesterase 1 (PDE1), useful for the treatment of diseases or disorders characterized by disruption of or damage to certain cGMP / PKG mediated pathways (e.g., in cardiac tissue). The invention further relates to pharmaceutical composition comprising the same and methods of treatment of cardiovascular disease and related disorders, e.g., congestive heart disease, atherosclerosis, myocardial infarction, and stroke.
Owner:INTRA CELLULAR THERAPIES INC
Novel uses
ActiveUS20150374699A1Significant modulatory activityImpact functionOrganic active ingredientsBiocidePhosphodiesteraseVascular disease
The invention relates to the administration of inhibitors of phosphodiesterase 1 (PDE1) for the treatment of diseases or disorders characterized by disruption of or damage to various cGMP / PKG mediated pathways. In one embodiment the invention relates to inhibitors of phosphodiesterase 1 (PDE1) for treatment of cardiovascular disease and related disorders, e.g., congestive heart disease, atherosclerosis, myocardial infarction, and stroke.
Owner:INTRA CELLULAR THERAPIES INC
Macrocycles as PDE1 inhibitors
Owner:H LUNDBECK AS
Triazolopyrazinones as PDE1 inhibitors
Owner:H LUNDBECK AS
1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
![1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors](https://images-eureka.patsnap.com/patent_img/97b92188-a95e-4c38-b6d6-bbffccef5d8f/US10766893-C00001.png "1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors")
![1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors](https://images-eureka.patsnap.com/patent_img/97b92188-a95e-4c38-b6d6-bbffccef5d8f/US10766893-C00002.png "1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors")
![1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors](https://images-eureka.patsnap.com/patent_img/97b92188-a95e-4c38-b6d6-bbffccef5d8f/US10766893-C00003.png "1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors")
Owner:H LUNDBECK AS
Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors
ActiveUS20210009571A1Avoid unnecessary influenceOrganic active ingredientsNervous disorderEnzyme Inhibitor AgentPyridazine
The present invention provides compounds of formula (I) that are PDE1 enzyme inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating disorders using the compounds of the invention.
![Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors](https://images-eureka.patsnap.com/patent_img/02c7282a-c333-4e0c-826a-a51a4e5c1776/US20210009571A1-C00001.png "Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors")
![Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors](https://images-eureka.patsnap.com/patent_img/02c7282a-c333-4e0c-826a-a51a4e5c1776/US20210009571A1-C00002.png "Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors")
![Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors](https://images-eureka.patsnap.com/patent_img/02c7282a-c333-4e0c-826a-a51a4e5c1776/US20210009571A1-C00003.png "Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors")
Owner:H LUNDBECK AS
Tricyclic derivative
Disclosed are compounds useful as inhibitors of phosphodiesterase 1 (PDE1), compositions thereof, and methods of using the same.
Owner:SUMITOMO DAINIPPON PHARMA CO LTD +1
Novel uses
ActiveUS20210213018A1Reduce expressionRegulates inflammatory activityOrganic active ingredientsSenses disorderDiseasePDE1
The disclosure provides the administration of inhibitors of phosphodiesterase 1 (PDE1) for the treatment and prophylaxis of diseases or disorders characterized by inflammation, e.g., neuroinflammation, including methods of treatment and pharmaceutical compositions for use therein.
Owner:INTRA CELLULAR THERAPIES INC
Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as PDE1 inhibitors
ActiveUS10633382B2Avoid unnecessary influenceNervous disorderOrganic chemistryEnzyme Inhibitor AgentPyrazine
Owner:H LUNDBECK AS
Method of treating a CNS injury with a PDE1 inhibitor
ActiveUS9545406B2Improve regenerative abilityImprove the level ofNervous disorderDisease diagnosisCns diseasePhosphodiesterase
The subject matter generally relates to methods of treatment and / or prophylaxis of CNS diseases, disorders, and / or injuries. In one aspect, the subject matter relates to inhibitors of phosphodiesterase 1 (PDE1) as neuroprotective agents and / or neural regenerative agents. In a further aspect, the subject matter relates to individuals that are at risk for the development of CNS disease or disorder.
Owner:INTRA CELLULAR THERAPIES INC
Organic compounds
ActiveUS20160039829A1Promote maladaptive hypertrophic gene expressionRegulating cGMP/PKGOrganic active ingredientsBiocidePhosphodiesteraseVascular disease
The invention relates to novel inhibitors of phosphodiesterase 1 (PDE1), useful for the treatment of diseases or disorders characterized by disruption of or damage to certain cGMP / PKG mediated pathways (e.g., in cardiac tissue). The invention further relates to pharmaceutical composition comprising the same and methods of treatment of cardiovascular disease and related disorders, e.g., congestive heart disease, atherosclerosis, myocardial infarction, and stroke.
Owner:INTRA CELLULAR THERAPIES INC
Bicyclic imidazolo derivative
InactiveUS20180044343A1Effective inhibitorNervous disorderOrganic chemistryPDE1Combinatorial chemistry
Disclosed are compounds, having the following structure, useful as inhibitors of Phosphodiesterase 1 (PDE1), compositions comprising the compounds, and methods of using the same.
Owner:SUMITOMO DAINIPPON PHARMA CO LTD
Compounds and methods
ActiveUS20170291904A1Increase level of intracellular cAMPPromoting neurite outgrowthOrganic active ingredientsSenses disorderCns diseasePhosphodiesterase
The subject matter generally relates to compounds and methods of treatment and / or prophylaxis of CNS diseases, disorders, and / or injuries. In one aspect, the subject matter relates to inhibitors of phosphodiesterase 1 (PDE1) as neuroprotective agents and / or neural regenerative agents. In a further aspect, the subject matter relates to individuals that are at risk for the development of CNS disease or disorder.
Owner:INTRA CELLULAR THERAPIES INC
Novel uses
ActiveUS20160045507A1Increase level of intracellular cAMPPromoting neurite outgrowthBiocideNervous disorderCns diseasePhosphodiesterase
The subject matter generally relates to methods of treatment and / or prophylaxis of CNS diseases, disorders, and / or injuries. In one aspect, the subject matter relates to inhibitors of phosphodiesterase 1 (PDE1) as neuroprotective agents and / or neural regenerative agents. In a further aspect, the subject matter relates to individuals that are at risk for the development of CNS disease or disorder.
Owner:INTRA CELLULAR THERAPIES INC
Organic compounds
The disclosure relates to methods of administering comprising administration of inhibitors of phosphodiesterase 1 (PDE1) for the treatment and / or prophylaxis of renal disorders, such as chronic kidney disease. Related compounds and methods of making are further defined.
Owner:INTRA CELLULAR THERAPIES INC
Haemophilus influenzae immunogen
The present invention provides immunogens which can be used for vaccines against non-typeable Haemophilus influenzae (NTHi). The protein targeted is NTHi PDE1 and is highly conserved making it a vital component necessary for bacterial pathogenesis. The protein preferably includes the C terminal fragment after cleavage between Asn269 and Gly270, when compared to the wild-type PDE1 amino acid sequence. Nucleic acid sequences, amino acid sequences, immunogenic compositions, treatments and methods of diagnosis are disclosed.
Owner:IOWA STATE UNIV RES FOUND